XML 50 R43.htm IDEA: XBRL DOCUMENT v3.26.1
Segments - Schedule of Reportable Segment Loss (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Segment Reporting [Line Items]        
Stock-based compensation expense $ 3,272 $ 1,384 $ 5,463 $ 2,592
Interest income, net (2,696) (1,407) (4,392) (2,532)
Net loss 17,797 12,301 30,989 22,641
Segment [Member]        
Segment Reporting [Line Items]        
Chronic cough in IPF clinical trial expense 4,347 3,039 6,034 5,921
Refractory chronic cough clinical trial expense 2,028 434 3,106 1,252
Clinical trial material 2,351 330 3,904 564
Other clinical trials and studies [1] 1,144 1,269 2,443 1,317
Other clinical development expenses [2] 1,848 1,861 3,371 3,279
Employee compensation (excluding stock compensation expense) 3,347 2,818 6,506 5,775
Stock-based compensation expense 3,272 1,384 5,463 2,592
Other segment items [3] 2,156 2,573 4,554 4,473
Interest income, net (2,696) (1,407) (4,392) (2,532)
Net loss $ 17,797 $ 12,301 $ 30,989 $ 22,641
[1] Includes expense related to the Company’s Phase 1 NDA supportive studies
[2] Includes expense related to general research and development activities, regulatory, medical affairs, and quality assurance.
[3] Includes general administrative expense, other (expense) income, net and income tax benefit.